• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Tepezza (teprotumumab-trbw)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Tepezza (teprotumumab-trbw)

  • Profile

Profile

Contact Information

Contact: Horizon Therapeutics
Website: https://www.tepezza.com/

Currently Enrolling Trials

    Show More

    General Information

    Tepezza (teprotumumab-trbw) is an insulin-like growth factor-1 receptor inhibitor.

    Tepezza is specifically indicated for the treatment of thyroid eye disease.

    Tepezza is supplied as a solution for intravenous injection administration. The recommended dose is an intravenous infusion of 10 mg/kg for the initial dose followed by an intravenous infusion of 20 mg/kg every three weeks for 7 additional infusions.  

    Mechanism of Action

    Teprotumumab-trbw’s mechanism of action in patients with Thyroid Eye Disease has not been fully characterized.  Teprotumumab-trbw binds to IGF-1R and blocks its activation and signaling. 

    Side Effects

    Adverse effects associated with the use of Tepezza may include, but are not limited to, the following:

    • muscle spasm
    • nausea
    • alopecia
    • diarrhea
    • fatigue
    • hyperglycemia
    • hearing impairment
    • dry skin
    • dysgeusia
    • headache

    Clinical Trial Results

    The FDA approval of Tepezza was based on results from a Phase 2 clinical study, as well as the Phase 3 confirmatory clinical study, OPTIC.

    The phase 2 study, the results of which were published in The New England Journal of Medicine in May of 2017, was multicenter, double-masked, randomized, placebo-controlled trial to determine the efficacy and safety of teprotumumab in patients with active, moderate-to-severe ophthalmopathy. A total of 88 patients were randomly assigned to receive placebo or active drug administered intravenously once every 3 weeks for a total of eight infusions. The primary end point was the response in the study eye. This response was defined as a reduction of 2 points or more in the Clinical Activity Score (scores range from 0 to 7, with a score of ≥3 indicating active thyroid-associated ophthalmopathy) and a reduction of 2 mm or more in proptosis at week 24. In the intention-to-treat population, 29 of 42 patients who received teprotumumab (69%), as compared with 9 of 45 patients who received placebo (20%), had a response at week 24.

    The phase 3 OPTIC study was a randomized, double-masked, placebo-controlled, parallel-group, multicenter study enrolled 83 subjects with moderate-to-severe active TED. Significantly more patients treated with Tepezza (82.9%) had a meaningful improvement in proptosis (≥ 2 mm) as compared with placebo patients (9.5%) without deterioration in the fellow eye at Week 24.

    In a related analysis of the Phase 2 and Phase 3 clinical studies, there were more patients with complete resolution of diplopia among those treated with Tepezza (53%) compared with those treated with placebo (25%). The majority of adverse events related to Tepezza included muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dry skin, dysgeusia and headache.

    Approval Date: 2020-01-01
    Company Name: Horizon Therapeutics
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • SurveywBlueBackground-360x240.png

      Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

    • TrendsInsights2023-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Two

    • TimeMoneyEffort-360x240.png

      Time is Money and So Is Effort, Budgeting Experts Say

    • TrendsInsights2023A-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Three

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing